Tag Archives: RESI

RESI San Francisco Panel Announcement: Corporate VCs & Strategic Investment

3 Nov

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking externally for innovative technologies, and strategic venture investments are a key part of many firms’ strategies for participating in the early stage ecosystem.  Firms may use subsidiary corporate venture funds, or may have an internal unit for making strategic investments in startups that are relevant to their pipeline.

At RESI San Francisco on Tuesday January 10th, the Corporate VC panel will bring together investors from 5 different corporate VCs to cover how they invest on behalf of their parent pharma companies.

The panelists are:

In this panel, corporate VC investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and how they bridge the gap between early stage startups and major pharmaceutical corporations.

If you’d like to be there in person, you can register for RESI now.

resi-san-francisco-2017

RESI San Francisco 2017 Panel Announcement: Early Stage Therapeutics Investors

27 Oct

By Caitlin Kramer, Research Analyst, LSN

caitlin-wp

The critical early years of drug development after lead compound selection see pre-clinical studies, IND-filing, and the design and implementation of clinical trials. While navigating the regulatory needs of the FDA may seem enough of a challenge, entrepreneurs must also consider how their drug addresses the needs of investors. Capital intensity, endpoint selection, timelines to inflection points – these are just a few topics beyond the scientific data that LSN researchers have discussed the importance of with investors.

Understanding what investors are looking for in the deal and business plan structure can help entrepreneurs immensely in their approach to funding. LSN is pleased to announce the Early Stage Therapeutics Investors panel for RESI SF 2017, where five therapeutics investors will share their perspective on evaluating deals and answer audience questions.

Joining moderator Doug Fisher, Partner, InterWest Partners:

Check out these investors’ bios, and if you haven’t registered yet, do so here or get in touch with us by reaching out to the RESI team at RESI@lifesciencenation.com.

237521341025992000

resi-san-francisco-2017

Early Bird Rate Extended

21 Oct

Attention:

We are currently experiencing technical issues regarding RESI Registration due to the wide spread internet outages. We will be extending the RESI Earlybird Rate through Monday, 10/24 at 5pm ET. We apologize for any inconvenience!

If you have any questions, please call (617) 580-5013 or email RESI@lifesciencenation.com

The Investors You’ll Meet at RESI San Francisco

20 Oct

By Caitlin Kramer, Research Analyst, LSN

caitlin-wp

Registration for RESI SF 2017 has been open for only a little over a month, and already 239 investors across 158 firms are registered. To illustrate who these 158 firms are, the below shows a breakdown of registered investment firm categories. VC firms have a large showing, followed by Corporate Venture groups and large pharmaceutical/biotech companies active in equity investing and early stage partnering.

 

Click to See More Confirmed Investors

Of the 239 investors registered thus far, 67% have a decision maker role at their firm, such as Director, VP, Partner or a C-Suite title. Only 16% are entry level investment professionals responsible for sourcing and preliminary screening. Of the remainder, most hold other managerial and sourcing roles; in addition, 6% of the investor attendees are angel investors. This abundance of active early stage life science investors and decision makers is unparalleled. Check out the below list of investors that have already registered, and keep in mind that many more will be added in the months leading up to the date of RESI SF on January 10th. We add new confirmed investors to the website every few days – keep up to date here.  You have until Friday October 21st to sign up for RESI at the Earlybird rate – that’s tomorrow!

162801425610010374

resi-san-francisco-2017

 

Panel Announcement: Big Data in Healthcare

20 Oct

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

LSN is pleased to publish its first panel announcement for RESI SF 2017: Big Data in Healthcare. On January 10th, a panel of five expert healthcare investors will speak regarding why they’re looking for big data investment opportunities, how they identify technologies that will have an impact on the healthcare system landscape, and what early-stage fundraising companies in this exciting new vertical can do to get a foot in their doors.

The Big Data in Healthcare panel will comprise of the following panelists:

The big data space has increasingly become exciting with its potential to transform healthcare through its cross-correlation of a number of broad applications – computer vision, machine learning, patient medical records, disease diagnoses, mental health trends and proposed therapies, as well as many other spaces in healthcare. If you haven’t yet, be sure to register now for this tremendous educational opportunity in this booming space, while also having the chance to meet valuable investors in-person.

162801425610010374

resi-san-francisco-2017

RESI Panel Announced: Asia Pacific Investors

13 Oct

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Numerous Asian-based venture firms have created investment offices in the states to uncover U.S. technology that fills an unmet need back home. These investors are looking to acquire an early stake and shepherd innovative products through the unfamiliar regulatory agencies/process, business environment and healthcare system at large.

LSN has recently recognized this trend with a dedicated track to explore these investor’s specific appetite and first-hand insight into cross-border deals, and we’re excited to bring these panels to the West Coast where there is a large amount of such activity.

Asia Pacific Investors panelists will include the following:

By registering for RESI San Francisco on January 10 (Tuesday of JPM week), you’ll be able to listen to these investors discuss the technologies they’re seeking in the US and how they can drive value by leveraging overseas networks and infrastructure.  The RESI Asia-North America Track will provide numerous opportunities to expand your network in the life sciences and learn more about the fundraising process in general.

162801425610010374

resi-san-francisco-2017

Behind the Curtain of RESI Partnering

6 Oct

Natasha Eldridge, Marketing Manager – RESI Conference Series, LSN

Organizing RESI Partnering was an amazing experience for me, and with the help of Alisdair Stamps from Meeting-Mojo, RESI Boston successfully had more than 1,300 meetings.

Now, I would like to remove the curtains as the Wizard of Oz or RESI and share a few tips on what I learned about partnering and getting meetings with investors.

Investor Profiles Are Filled Out in Depth

I have been to many partnering conferences and rarely see investor profiles filled out besides the name of the attendee representing the firm. A strong differentiator of the RESI Conferences is LSN’s ability to populate investor profiles with their up-to-date investment preferences and criteria. The reason for this is to help fundraising companies make the most of their time by meeting with the right investors.

Through the search options, you can find investors that are actively investing in your technology type, indication, and phase of development. You don’t have to imagine a list of investors looking specifically for your asset(s) because we put that list together for you.

It’s a Numbers Game

One request to a few investors is not going to cut it. You can generate your list by using the search function – now use it.  Research and message the entire list of investors.  At LSN, sometimes we have to contact investors 5, 10 or 25 times to get a response, and we know the investors! Don’t be disappointed if you do not hear from an investor immediately.  They may be very distracted by other matters, or out of the office on a trip. The point is they are busy, so keep messaging them until you get a response.

Partnering Requests Are a 10-Second Pitch, Not a 350-Page Novel

Actually, according to a recent study by Microsoft most people have an attention span less than a goldfish, or just 8 seconds. Now that you know an investor might spend about 8 seconds reading your request, what do they need to know about your company. Well, it only takes these 6 key elements to get your message across in a short amount of time.

1st — Introduce Yourself

Introduce yourself, your title, and the name of your company. Although obvious, you might be surprised by how many people don’t do this.

2nd — Introduce Your Company

Give a brief overview of your company so that an investor can determine from the first sentence whether you are a fit for their investment mandate. Remember, every investor is unique and therefore not every investor is a fit for your opportunity. Here are five key data points that are likely to affect investor fit:

Where your company is based

What sector your company is in (biotech, medtech, diagnostics, healthcare IT, etc)

The modality you are using

The indication you are treating or problem you are trying to solve

Your product’s development phase

3rd — Key Value Proposition/Elevator Pitch

Use the next part of the email to describe the key value proposition of your technology. This should include a high-level description of the core technology and its major differentiators from currently available products or solutions. This is the core of your messaging and should reveal enough information to pique interest.

4th — The Stage of Your Fundraising Campaign

You should clearly state where you are in the fundraising process (beginning, middle or end) and what the use of those proceeds will be. This way an investor can gauge if your round is a fit for their capital allocation.

5th — Reaffirm

You should do your homework on every investor you reach out to and reference a relevant data point to reaffirm the reason you are reaching out.

6th — The Next Step

Finish the email by laying out when you plan on connecting with them and how the both of you should connect. As this is a conference partnering message, this can be as simple as telling them to accept the meeting request if they would like to meet up.

By sticking to these fundamentals you will make it a lot easier for an investor to identify you as a fit for their investment strategy. This will lead to higher response rates and more productive meetings.

Company Marketing Materials Need to be On Point

Take a look at your marketing material. Is it full of graphs, charts and before & after pictures of mice? Can an investor immediately identify the value proposition of the company and products? Humans relate to stories and investors are the same. Make sure your charts, graphs and pictures (and words) are creating an amazing story about your assets. Again, do not create a novel to tell your story. Stick with a maximum 2-page Executive Summary and 10-12-page PowerPoint Pitch Deck.

So What, You Had a Few Scheduled Meetings? Ad-Hoc Meetings Matter

I have spoken with several investors who enjoy meeting companies on the fly, after a panel session, or during the cocktail reception. I have also spoken with several companies who got funded by talking to investors companies on the fly, after a panel session, or during the cocktail reception. Either way investors and fundraising companies are using the RESI Conference to build relationships. Sometimes you will hit it out the park on your first time at bat or first RESI Conference and get funded and sometimes you need a few more times at the plate to get your first hit or attend several RESI Conferences to meet the right investor.

Partnering opens for RESI San Francisco on December 5th. Take this time to get prepared and I will see you in San Francisco.

162801425610010374